Neuromuscular Blockade: Difference between revisions
No edit summary |
No edit summary |
||
| Line 22: | Line 22: | ||
[https://pubmed.ncbi.nlm.nih.gov/26646837/ Sugammadex and rocuronium-induced anaphylaxis] | [https://pubmed.ncbi.nlm.nih.gov/26646837/ Sugammadex and rocuronium-induced anaphylaxis] | ||
[https://www.bjaopen.org/article/S2772-6096(22)00091-0/fulltext Safety of sugammadex for myasthaenia gravis patients undergoing general anaesthesia: a retrospective database study] | |||
Revision as of 14:58, 17 October 2022
This is a Stub Notice. This page has not been completed. You can work on this page by signing in and going to the Edit tab. Thanks for helping to make PedsAnesthesia.Net Wiki useful.
Go to the Main Page to see the Topic Outline.
Go to the Generalized Suggested Outline for information on case-specific details for each page.
Go to the Test Page for examples on how to use references in the page.
Relevant Article Depot:
Neuromuscular blockade in children
Test Your Knowledge: unique advantage of rocuronium
Faulk DJ, Austin TM, Thomas JJ, Strupp K, Macrae AW, Yaster M. A Survey of the Society for Pediatric Anesthesia on the Use, Monitoring, and Antagonism of Neuromuscular Blockade. Anesth Analg 2021;132:1518-26.
Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev 2017;8:Cd012763.
Hristovska AM, Duch P, Allingstrup M, Afshari A. The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis. Anaesthesia 2018;73:631-41.
Saager L, Maiese EM, Bash LD, Meyer TA, Minkowitz H, Groudine S, Philip BK, Tanaka P, Gan TJ, Rodriguez-Blanco Y, Soto R, Heisel O. Incidence, risk factors, and consequences of residual neuromuscular block in the United States: The prospective, observational, multicenter RECITE-US study. J Clin Anesth 2019;55:33-41.